Redwood City, CA – July 22, 2015 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that it has raised $43 million in an equity financing. The equity financing was co-led by new investor Endeavour Vision, a technology [...]
Zurich‐Schlieren, July 07, 2015. Molecular Partners AG (ticker: MOLN) today announced that its partner Allergan has initiated phase III clinical trials with abicipar pegol (abicipar) for the treatment of wet age‐related macular degeneration (wet AMD). The event triggered a clinical milestone payment to Molecular Partners of USD 15 million. [...]
Acquisition Supports Strategy to Expand into Higher Value Storage Platforms and Systems IRVINE and MILPITAS, Calif., March 3, 2015 /PRNewswire/ — Western Digital® Corporation (NASDAQ: WDC) announced today that HGST has entered into a definitive agreement to acquire Amplidata, a privately-held developer of object storage software for public and [...]
Acquisition Expands Merck’s Oncology Portfolio with Novel Oral BET Inhibitor, OTX015 KENILWORTH, N.J., Dec. 18, 2014 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug [...]
Zurich-Schlieren, December 5, 2014. Molecular Partners AG announces that the total offer size of the initial public offering (“IPO”) amounts to CHF 106.2 million, of which gross proceeds from the primary shares issued are CHF 104.1 million. The Joint Bookrunners of Molecular Partners’ IPO have partially exercised the over-allotment [...]
MOUNTAIN VIEW, Calif., Dec. 4, 2014 /PRNewswire/ — PneumRx, Inc. www.pneumrx.com, a leader in the field of interventional pulmonology, today announced that it has signed an agreement to be acquired by BTG Plc (LSE:BTG) in a deal worth up to $475 million, based on an initial consideration of $230 [...]
Zurich-Schlieren, November 4, 2014. Molecular Partners AG has successfully re-launched its Initial Public Offering (IPO). Due to strong interest and demand from both international and Swiss institutional and private investors, Molecular Partners accelerated the timetable and closed the bookbuilding process yesterday, Monday, 5pm CET. Molecular Partners AG has successfully [...]
Symetis Joins Industry Leaders Edwards Lifesciences and Medtronic as Only Companies to Offer Both Transapical and Transfemoral Options for Transcatheter Aortic Heart Valve Delivery LAUSANNE, SWITZERLAND–(Marketwired – Sept. 12, 2014) – Symetis SA, the leading European developer of transcatheter aortic valve implantation (TAVI) systems, announced today the launch of [...]
By Chris Reidy | GLOBE STAFF JUNE 19, 2014 – Bind Therapeutics Inc., a Cambridge-based nanomedicine company that is developing programmable drugs to certain types of cancer, said Thursday it has entered into a research agreement with Swiss drug giant Roche to discover novel treatment of diseases in therapeutic [...]
Partnership will combine novel biologics (DARPins) with Roche drug-conjugate technology Basel, Switzerland / Zurich-Schlieren, Switzerland, 04 December 2013. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics [...]